Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NanoCarrier, Kirin to Collaborate on Novel Anticancer Agents
December 9, 2002
- Bayer AG Actively Seeking Alliance: Mr Wenning
December 9, 2002
- Astis: Sales Up 0.9% to \44.7 Bil.
December 9, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 9, 2002
- Sankyo to Spin Off Agricultural Chemicals, Specialty Products
December 9, 2002
- Seiwa Sangyo: 4.5% Increase in Sales Boosts Profits
December 9, 2002
- Kobayashi Pharma: New Products, Cost-cutting Boost Sales and Profits
December 9, 2002
- BUSINESS NEWS IN BRIEF
December 9, 2002
- Sales of Tacrolimus to Reach \100 Bil. Worldwide: Dr Aoki of Fujisawa
December 9, 2002
- OTC NEWS IN BRIEF
December 9, 2002
- Amarin Targets Major Drug Companies in Japan: Mr Downie
December 9, 2002
- Sanki: Net Profits Up 42.4% with 3.1% Rise in Sales
December 9, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 9, 2002
- 27 Listed Drug Firms: Sales Up 4.1%, Net Profits Down 8.4%
December 9, 2002
- Ohki: Profits Leap with 8.6% Rise in Sales
December 9, 2002
- MEDICAL DEVICE NEWS IN BRIEF
December 9, 2002
- Taisho: Sales Flat, Ordinary and Net Profits Slip
December 9, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
December 9, 2002
- WORLD NEWS IN BRIEF
December 9, 2002
- Banyu: NHI Price Cuts, Higher R&D Spending Reduce Net Profits by 52.6%
December 9, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…